# Aptamer making significant progress commercially and technically

- Link: https://www.directorstalkinterviews.com/aptamer-making-significant-progress-commercially-and-technically/4121174819
- Published: 2024-10-22T07:29:49+01:00
- Author: Amilia Stone

**Aptamer Group plc** (LON:APTA), the developer of novel Optimer^(®) binders to 
enable innovation in the life sciences industry, has announced its full year results
for the twelve months ended 30 June 2024.

**Highlights**

·      New strategic approach launched in August 2024 with a focus on the development
and partnering of high-value Optimer assets with licensing potential.

·      Group reorganisation with a refreshed Board and cost base reduced to enable
strategy delivery.

·      Dr Adam Hargreaves appointed Non-Executive Chair of Aptamer Group, Dr Arron
Tolley re-appointed as Chief Executive Officer, Andrew Rapson appointed as Chief
Financial Officer in August 2024 and Tim Sykes appointed to the Board as Non-Executive
Director in September 2024.

·      Commercial pipeline rebuilt with increasing revenue momentum in the second
half of the financial year and £1.0 million in orders won in the last quarter.

·      Delivering on our strategic milestones, including:

·      Increased commercial traction and advancing to licensing of critical reagent
with a top five pharmaceutical partner.

·      Planned on-person functionality tests of Optimer as active ingredient in 
deodorants by Unilever, with the potential for further development and downstream
licensing if successful.

·      Second phase of Optimer development for early Alzheimer’s disease lateral
flow test.

·      Proof of fibrotic liver delivery vehicle with AstraZeneca’s siRNA payload.

·      Planned identification of the fibrotic liver biomarker to satisfy significant
interest from multiple partners and support the mechanism of action, which has the
potential to unlock multiple significant high-value deals.  

**Financial summary**

·      Revenue £0.9 million (2023: £1.8 million).

·      Cash balance at 30 June 2024 £0.9 million (2023: £0.2 million).

·      Adjusted EBITDA loss of £2.8 million (2023: £4.7 million).

·      Administration expenses £3.2 million (2023: £5.0 million).

·      £3.5 million net proceeds received from equity raising in August and September
2023.

**Post-period end**  

·      Successful fundraise in August 2024 of £2.6 million (net).

·      Further to project with a genetic medicines biotechnology company in December
2023,^(1) completed development of the Optimer delivery vehicle and shipped material
to the partner for testing. This delivery vehicle could form a critical part of 
precision gene therapy with the potential for downstream licensing.

·      Developed Optimer binders for a new non-invasive prenatal diagnostic platform
that avoids amniocentesis, with material shipped to Bioliquid Innovative Genetics
for testing on human samples.

·      Revenue from contracts progressing through the laboratory of £0.9 million,(
subject to scientific attrition), including contracts with top 10 pharmaceutical
companies and many of these contracts with licensing potential. 

> **Commenting on the results, Arron Tolley, Chief Executive Officer of Aptamer 
> Group, said:** “Over the past year, we have made significant progress commercially
> and technically, under challenging market conditions. The Group has focused on
> three key aspects of our strategy, being 1. internal asset development, 2. regaining
> commercial traction and 3. cost discipline. We have rebuilt and expanded the pipeline
> over the year, demonstrating a positive trajectory in revenue recognition with
> 65% of the year’s total revenue realised in the second half and increased our 
> collaborations with top ten pharmaceutical partners. We have underscored the growing
> demand for Optimer technology and the rising recognition of our platform within
> the industry.   
> “Aptamer’s strong technical delivery across both immunohistochemistry (IHC) and
> gene therapy delivery has been instrumental in driving commercial interest. The
> Group has secured an increasing number of contracts for Optimer IHC development,
> reinforcing our growing reputation in this segment of the market. In the drug 
> delivery space, data generated internally facilitated the signing of a substantial
> contract for Optimer delivery vehicles for gene therapies and initiated a post-
> period collaboration with AstraZeneca to explore the use of our molecules for 
> drug delivery in fibrotic liver disease.
> “The Group’s partnership with Unilever has made considerable progress towards 
> the use of Optimer binders in treating malodour in deodorant products. Finally,
> a soft launch of our new Optimer+ platform has been well received across the industry,
> leading to two new contracts, one with a top ten pharmaceutical partner, in the
> first few months of launch. This provides us with a unique position within the
> market to continue progression.  
> “These developments have been made in parallel with substantial reductions to 
> the cost base and a continued commitment to tight cost discipline supporting the
> future of the Group. We thank investors for their support during our placing in
> August 2024, which enables us to focus on advancing our Optimer assets and pursuing
> new opportunities through additional partnerships.”

^(1.        ) ^([Aptamer Group signs material agreement with genetic medicines company](https://polaris.brighterir.com/public/aptamer_group/news/rns/story/rdly38x))

Share on:
